The field of hematologic oncology stands at the threshold of a transformative era with the groundbreaking approval of EPKINLY (epcoritamab), the world's first CD20xCD3 bispecific antibody therapy for diffuse large B-cell lymphoma (DLBCL). This extraordinary therapeutic achievement represents the convergence of cutting-edge biotechnology, precision medicine...